We therefore investigated the effects of HSP90 modulation in response to the combination of trastuzumab, pertuzumab, and 4-OH tamoxifen in the BT474 HER2+/ER-positive breast cancer cell line. This evidence concerns the gene HSP90AA1 and breast carcinoma.